The potential explanation for such unexpected pro‐metastasis effects following IL6‐targeted treatment may be due to the abrogation of IL6‐STAT3 signalling‐mediated regulation of tumour suppressors such as TP53 (Pencik et al, 2015). The gene discussed is TP53; the disease is neoplasm.